P827: EFFICACY AND SAFETY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL

• H. Yamazaki,
• J. W. Lee,
• J. H. Jang,
• M. Sawa,
• M. Kizaki,
• Y. Tomiyama,
• K. Nagafuji,
• K. Usuki,
• J.-P. Gau,
• Y. Morita,
• J.-L. Tang,
• H. Chang,
• M. Noshiro,
• A. Matsuda,
• K. Ozawa,
• K. Mitani,
• Y. Kanda,
• S. Nakao

Affiliations

H. Yamazaki

1 Kanazawa University Hospital, Ishikawa, Japan

J. W. Lee

2 Seoul St. Mary’s Hospital​

J. H. Jang

3 Samsung Medical Center​, Seoul, South Korea

M. Sawa

4 Anjo Kosei Hospital, Aichi

M. Kizaki

5 Saitama Medical Center, Saitama

Y. Tomiyama

6 Osaka University Hospital, Osaka

K. Nagafuji

7 Kurume University Hopital, Fukuoka

K. Usuki

8 NTT Medical Center Tokyo, Tokyo, Japan

J.-P. Gau

9 Taipei Veterans General Hospital​, Taipei, Taiwan

Y. Morita

10 Kindai University Hospital, Osaka, Japan

J.-L. Tang

11 National Taiwan University Hospital​, Taipei

H. Chang

12 Chang Gung Medical Foundation- Linkou Branch​, Taoyuan, Taiwan

M. Noshiro

13 Kyowa Kirin Co.,Ltd., Tokyo

A. Matsuda

14 Saitama Medical University International Medical Center, Saitama

K. Ozawa

15 Jichi Medical University Hospital

K. Mitani

16 Dokkyo Medical University Hospital, Tochigi, Japan

Y. Kanda

15 Jichi Medical University Hospital

S. Nakao

1 Kanazawa University Hospital, Ishikawa, Japan